# Odyssey Therapeutics, Inc.: overview ODTX · Nasdaq · CIK 1882782 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31 Pages: [Overview](/companies/odtx.md) · [Financials](/companies/odtx/financials.md) · [Filings](/companies/odtx/filings.md) · [Insiders](/companies/odtx/insiders.md) Latest reported revenue: [$0](/filings/0001193125-26-335822.md) for Q2 FY2026, three months to 2026-06-30, from the 10-Q filed Aug 6, 2026 (XBRL us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax, accession 0001193125-26-335822). ## Last eight quarters | Line item | Unit | period not labelled (2025-03-31) | period not labelled (2025-06-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | | Revenue | $m | [1.9](/filings/0001193125-26-274290.md) | [1.0](/filings/0001193125-26-335822.md) | [0.0](/filings/0001193125-26-274290.md) | [0.0](/filings/0001193125-26-335822.md) | | Gross margin | % | not reported | not reported | not reported | not reported | | Operating margin | % | [(2041.7%)](/filings/0001193125-26-274290.md) | [(4371.3%)](/filings/0001193125-26-335822.md) | not reported | not reported | | Net margin | % | [(2003.9%)](/filings/0001193125-26-335822.md) | [(4299.8%)](/filings/0001193125-26-335822.md) | not reported | not reported | | Diluted EPS | $ per share | [(39.37)](/filings/0001193125-26-274290.md) | [(29.54)](/filings/0001193125-26-335822.md) | [(6.77)](/filings/0001193125-26-274290.md) | [(1.74)](/filings/0001193125-26-335822.md) | | Free cash flow | $m | [(39.5)](/filings/0001193125-26-274290.md) | [(34.3) d](/filings/0001193125-26-335822.md) | [(41.2)](/filings/0001193125-26-274290.md) | [(34.7) d](/filings/0001193125-26-335822.md) | - Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 6-month figure less the 3-month figure. ## Last five fiscal years Not reported. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/odtx/insiders.md) None in coverage. ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [FMR LLC](/funds/315066.md) | 2026-06-30 | $96.9m | 5,179,262 | | New +5,179,262 | | [SR One Capital Management, LP](/funds/1910264.md) | 2026-06-30 | $71.0m | 3,794,883 | | New +3,794,883 | | [TPG GP A, LLC](/funds/1903793.md) | 2026-06-30 | $69.0m | 3,690,146 | | New +3,690,146 | | [LIGHTSPEED MANAGEMENT COMPANY, L.L.C.](/funds/1702122.md) | 2026-06-30 | $67.5m | 3,608,443 | | New +3,608,443 | | [ORBIMED ADVISORS LLC](/funds/1055951.md) | 2026-06-30 | $56.2m | 3,001,198 | | New +3,001,198 | | [Sanofi](/funds/1121404.md) | 2026-06-30 | $37.3m | 1,991,918 | | New +1,991,918 | | [DEERFIELD MANAGEMENT COMPANY, L.P.](/funds/1009258.md) | 2026-06-30 | $19.6m | 1,046,139 | | New +1,046,139 | | [Sands Capital Alternatives, LLC](/funds/1846444.md) | 2026-06-30 | $16.4m | 875,000 | | New +875,000 | | [HHLR ADVISORS, LTD.](/funds/1762304.md) | 2026-06-30 | $15.6m | 831,656 | | New +831,656 | | [General Catalyst Group Management, LLC](/funds/1637946.md) | 2026-06-30 | $15.2m | 810,272 | | New +810,272 | ## Recent filings [All 69 filings](/companies/odtx/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-10-20 | 11:00 ET | [8-K](/filings/0001193125-26-425684.md) | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193125-26-425684 | | 2026-09-09 | 23:10 ET | [8-K](/filings/0001193125-26-385477.md) | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193125-26-385477 | | 2026-08-06 | 23:00 ET | [10-Q](/filings/0001193125-26-335822.md) | Quarterly report, period 2026-06-30 | 0001193125-26-335822 | | 2026-08-04 | 11:00 ET | [8-K](/filings/0001193125-26-331512.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-331512 | | 2026-06-23 | 12:45 ET | [8-K](/filings/0001193125-26-278581.md) | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193125-26-278581 | | 2026-06-17 | 20:45 ET | [10-Q](/filings/0001193125-26-274290.md) | Quarterly report, period 2026-03-31 | 0001193125-26-274290 | | 2026-06-17 | 20:45 ET | [8-K](/filings/0001193125-26-274291.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-274291 | | 2026-05-18 | 22:29 ET | [SCHEDULE 13D](/filings/0001072613-26-000468.md) | Ownership report, active investor | 0001072613-26-000468 | | 2026-05-18 | 20:06 ET | [SCHEDULE 13D](/filings/0001999371-26-011002.md) | Ownership report, active investor | 0001999371-26-011002 | | 2026-05-15 | 20:08 ET | [SCHEDULE 13D](/filings/0001193125-26-226695.md) | Ownership report, active investor | 0001193125-26-226695 | ## Latest annual report No annual report is in coverage. ## Forecast league Q3 FY2026, the quarter ended 2026-09-30, is open for forecasts until the first results filing for it is accepted by EDGAR. Results are due by \[object Promise\]. [Forecast this quarter](/leagues/2026q3/targets/8e6a98cf-83c1-4b6c-8966-d79ce33b3eb4) ## About the filer - CIK: 1882782 - Tickers: ODTX - Exchange: Nasdaq - SIC code: 2836 Biological Products, (No Diagnostic Substances) - State of incorporation: DE - Filer category:
Emerging growth company Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:51 ET. No prices; not investment advice.